Highlights from the Hoag Family Cancer Institute’s Clinical Trial Program

Thomas Wang, MD, PhD, FACS

Medical Director, Hoag Melanoma Program

Dr. Thomas Wang, a board-certified surgical oncologist, joined Hoag in February 2022. Previously, he spent 15 years with the University of Alabama at Birmingham (UAB), where he served as professor of surgery at the UAB Heersink School of Medicine and chief of surgical oncology for the Birmingham VA Medical Center. Dr. Wang’s clinical interests include melanoma, soft tissue sarcomas and endocrine surgery. He is an active member in multiple national surgical societies, including the Association for Academic Surgery, the Society of University Surgeons, the American Association of Endocrine Surgeons and the Society of Surgical Oncology.

Steven Wang, MD

Director of Dermatologic Oncology, Hoag Melanoma Program

Dr. Steven Wang joined Hoag in July 2022 from Memorial Sloan Kettering Cancer Center in New Jersey, where he was the head of the dermatology section and director of dermatologic surgery and dermatology. Dr. Wang specializes in the diagnosis, treatment and prevention of skin cancers with a focus on melanoma and the application of artificial intelligence and nanotechnologies. Dr. Wang is the co-founder of the Nanodermatology Society and serves as president of the Photodermatology Society and chair of the Photobiology Committee for the Skin Cancer Foundation.

Together, Dr. Thomas Wang and Dr. Steven Wang are partnering with community dermatologists to deliver a shared-care model with a tripartite approach focused on genetic testing, cutting-edge imaging and innovative surgical and therapeutic treatments. Applying this approach, the duo aims to streamline care and increase efficiency, effectiveness and accessibility for patients with a high risk of melanoma and other forms of skin cancer.

Dr. Thomas Wang (left) and Dr. Steven Wang (right)